{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:45:41Z","timestamp":1787013941882,"version":"build-2736575974"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    BRUIN CLL\u2010321 is the first prospective, randomized study conducted in covalent BTK inhibitor (cBTKi) pretreated chronic lymphocytic leukaemia\/small lymphocytic lymphoma (CLL\/SLL) patients. In this heavily pretreated population, pirtobrutinib significantly improved progression\u2010free survival (PFS) compared to investigator's choice (IC) of idelalisib\/rituximab (IdelaR) or bendamustine\/rituximab (BendaR). This report presents results from Chinese patients enrolled in BRUIN CLL\u2010321, who were randomized 1:1 to pirtobrutinib (200\u2009mg once daily) or IC of BendaR (idelalisib is not approved in China). End\u2010points included independent review committee (IRC)\u2010assessed PFS, investigator (INV)\u2010assessed PFS, overall survival (OS), event\u2010free survival (EFS), time to next treatment (TTNT) and safety. Among 40 Chinese patients (pirtobrutinib\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200919; BendaR\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200921), IRC\u2010assessed PFS favoured pirtobrutinib (stratified hazard ratio [HR]\u2009=\u20090.281; 95% confidence interval [CI], 0.070\u20131.125, nominal\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0554), with median PFS not reached versus 10.6\u2009months with BendaR; INV\u2010assessed PFS supported these findings. TTNT (HR\u2009=\u20090.150; 95% CI, 0.031\u20130.728) and EFS (HR\u2009=\u20090.322; 95% CI, 0.094\u20131.101) were also improved. A trend towards OS benefit was observed (HR\u2009=\u20090.343; 95% CI, 0.031\u20133.787). Pirtobrutinib showed a favourable safety profile, with fewer grade \u22653 treatment\u2010emergent adverse events (36.8% vs. 93.3%) and serious adverse events (15.8% vs. 46.7%). These findings support pirtobrutinib as a clinically active and tolerable option for cBTKi\u2010pretreated Chinese CLL\/SLL population.\n                  <\/jats:p>","DOI":"10.1111\/bjh.70334","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T03:36:04Z","timestamp":1769139364000},"page":"926-936","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia\/small lymphocytic lymphoma (\n                    <scp>CLL<\/scp>\n                    \/\n                    <scp>SLL<\/scp>\n                    ): Results from the phase 3 study\n                    <scp>BRUIN CLL<\/scp>\n                    \u2010321"],"prefix":"10.1111","volume":"208","author":[{"given":"Shuhua","family":"Yi","sequence":"first","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hematology The Affiliated Hospital of Xuzhou Medical University  Xuzhou China"},{"name":"Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital  Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Hematology Nanfang Hospital of Southern Medical University  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital  Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy The Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Nanchang University  Nanchang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai Yan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma Zhejiang Cancer Hospital  Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Lymphoma &amp; Hematology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuhan","family":"Hui","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xuanwu Hospital Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Hematology Gansu Provincial Cancer Hospital  Lanzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine Sun Yat\u2010Sen University Cancer Center  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhui","family":"Ye","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Sharman","sequence":"additional","affiliation":[{"name":"Willamette Valley Cancer Institute and Research Center US Oncology Research  Eugene Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College  Tianjin China"},{"name":"Tianjin Institutes of Health Science  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"NCCN.Clinical practice guidelines in oncology: chronic lymphocytic leukemia\/small lymphocytic lymphoma\u2014version 3.2025.2023. Available from:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv303"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0045"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(22)00293\u20105"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01460"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)30262\u20102"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010019\u20100602\u2010x"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102021\u2010147885"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.09.007"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.2282"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.23032"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000801"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03355"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201005\u2010850461"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation\u20102016.1.149"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)00224\u20105"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300696"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35339"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201000166"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102021\u2010146818"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf181"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201009\u2010806398"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.3748"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.840616"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12938\u2010021\u201000973\u20106"},{"key":"e_1_2_11_30_1","unstructured":"National Cancer Institute. Surveillance Epidemiology and End Results Program.Cancer Stat Facts: Leukemia\u2014chronic lymphocytic leukemia (CLL). Accessed Auguest 22 2025. Available from:https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70334","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70334","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:42:32Z","timestamp":1782106952000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/bjh.70334"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70334","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"2025-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}